Word: leukemias
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...background. I'm pure business. I'd be lying if I said I wasn't here to make a dollar out of it. But I would like to see organ cloning become a reality." He was inspired to launch the business, he says, after a young cousin died of leukemia. "There are megadollars involved, and everyone is racing to be the first," he says. As for his own slice of the pie, Sloan says he just sold his firm to a French company, which he refuses to name, and that he is heading for Hawaii. The Southern Cross factory address...
...reach. But if he left Switzerland, Israel or Spain, he risked getting bounced to New York to face criminal tax-evasion charges from 1983. Bounty hunters and U.S. Marshals set traps for him, and Rich missed his father's funeral--and later his daughter's when she died of leukemia in 1996. That's why, for the two decades after he fled the U.S., Rich has been trying to buy his way back to respectability by stroking the interests of the Israelis, Swiss, Spaniards and Americans, cultivating relationships like roses in his garden. From his outpost in the Swiss town...
...toiled in the political arena for nearly 50 years, winning the respect of Congressmen and common citizens alike. In light of this career of unwavering dedication, we were greatly saddened to learn Feb. 12 that Moakley will not be able to seek reelection due to an incurable form of leukemia...
...background. I'm pure business. I'd be lying if I said I wasn't here to make a dollar out of it. But I would like to see organ cloning become a reality." He was inspired to launch the business, he says, after a young cousin died of leukemia. "There's megadollars involved, and everyone is racing to be the first," he says. As for his own slice of the pie, Sloan says he just sold his firm to a French company, which he refuses to name, and he was heading for Hawaii last week. The Southern Cross factory...
Many of the new therapies also happen to be incredibly potent. Last month, for example, pharmaceutical giant Novartis reported spectacular results in a clinical trial of Glivec, a drug that disables a uniquely aberrant protein produced inside cells of chronic myelogenous leukemia, which afflicts 4,400 new patients in the U.S. each year. In the drug's very first test, every patient went into remission. In the most recent results, 30% showed no sign of the chromosomal damage that marks the disease and appeared to have been cured. "This drug is amazing," says Richard Stone, an oncologist at the Dana...